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Background. Oxidative stress plays a role in the pathogenesis of many chronic inﬂammatory lung diseases. Exhaled
breath condensate (EBC) collection is a noninvasive method to investigate pulmonary oxidative stress biomarkers such as
malondialdehyde (MDA). Subjects and Methods. We measured MDA levels in EBC in a large number of patients (N = 194)
with respiratory diseases: asthma (N = 64), bronchiectasis (BE, N = 19), chronic obstructive pulmonary disease (COPD,
N = 73), idiopathic pulmonary ﬁbrosis (IPF, N = 38). Fourteen healthy nonsmoking subjects were included as controls. Results.
Excluding IPF subjects, MDA levels were signiﬁcantly higher in all disease groups than in control group. MDA was signiﬁcantly
higher in COPD than asthmatic and BE subjects. Among asthmatics, corticosteroids-treated subjects had lower MDA levels than
untreated subjects. COPD subjects showed an inverse correlation between MDA concentrations and FEV1%( rh o :−0.24, P<. 05).
Conclusions. EBC-MDA is increased in subjects with chronic airway disorders, particularly in COPD, and it is related to FEV1
reduction.
1.Background
Oxidative stress plays an important role in the pathogenesis
ofmanychronicinﬂammatorylungdisorders,particularlyin
COPD and asthma, where it is an important consequence of
irritant-induceddamageofbronchialepithelialcellsandrep-
resentsanamplifyingmechanismthroughtherecruitmentof
i n ﬂ a m m a t o r yc e l l si nt h ea i r w a y s[ 1, 2].
Among the many biological targets of oxidative stress,
membrane lipids are the most commonly involved class
of biomolecules. Lipid peroxidation yields a number of
secondary products able to boost oxidative damage [3].
In addition to their cytotoxic properties, lipid peroxides
are increasingly recognized as being important in signal
transduction for a number of events in the inﬂammatory
response [4].
Exhaled breath condensate (EBC), obtained by cooling
exhaled air, has recently been proven as a good biological
tool to monitor inﬂammatory and oxidative stress of lower
respiratory tract [5] .S ev e ra lb i o m a r k e r sh a v eb e e nm e a s u r e d
in EBC, including aldehydes, H2O2, adenosine, isoprostanes,
leukotrienes and cytokines, and an increasing number of
studies report the use of EBC in the investigation of airway
lining ﬂuid composition in several respiratory diseases [6].
Malondialdehyde (MDA) has been widely studied as a
product of polyunsaturated fatty acid peroxidation. High
MDA levels have been observed in several biological ﬂuids
frompatientswithdiﬀerentairwaydiseasesincludingasthma
[7–11], COPD [11, 12], and bronchiectasis [13]. MDA in
EBC has been measured in relatively few studies [9–12], and
only few of them include large number of subjects [9, 10].
In this study, we measured and compared EBC levels of
MDA in a large group of subjects with diﬀerent pulmonary
diseases in order to explore the possible usefulness of this
measurement in the assessment of diﬀerent lung diseases.
2. Methods
2.1. Subjects. Exhaled breath condensate was collected from
194 subjects aﬀected by diﬀerent airway diseases attending
to our pulmonary unit. Patients with asthma (A, N = 64),
bronchiectasis (BE, N = 19), chronic obstructive pulmonary2 Mediators of Inﬂammation
Table 1: Main characteristics of the groups under study.
Disease No Age Gender (M/F) Smoking habit (yes/no/ex) FEV1 (% pred) ICS therapy (yes/no)
Healthy controls 14 40.4 ± 13.1 6/8 0/14/0 102.4 ± 8.9 0/14
Asthma (all) 64 45.8 ± 16.5 28/36 7/45/12 92.6 ± 13.9 41/23
ICS untreated 23 42.0 ± 14.7 8/15 3/14/6 99.0 ± 10.7 0/23
ICS treated 41 47.2 ± 17.7 20/21 4/31/6 88.7 ± 14.2 41/0
COPD (all) 73 71.1 ± 7.6 60/13 18/9/46 49.8 ± 17.7 73/0
Moderate 38 71.6 ± 7.3 29/9 11/6/21 63.3 ± 10.6 38/0
Severe 35 69.8 ± 7.8 31/4 7/3/25 34.3 ± 9.9 35/0
IPF 38 70.2 ± 7.4 16/22 3/19/16 78.0 ± 21.2 9/29
Bronchiectasis 19 55.5 ± 13.0 5/14 0/14/5 87.3 ± 22.0 13/6
FEV1: forced expiratory volume 1sec; ICS: inhaled corticosteroids; COPD: chronic obstructive pulmonary disease; IPF: idiopathic pulmonary ﬁbrosis.
disease (COPD, N = 73) and idiopathic pulmonary ﬁbrosis
(IPF, N = 38) were included in the study. Fourteen healthy
nonsmoking subjects were included as controls.
For each subject, diagnosis and assessment of sever-
ity for the diﬀerent diseases were performed according
to international guidelines recommendations [14–17]. In
particular, asthmatic patients were divided according to the
presence of regular treatment with inhaled corticosteroids,
whereasCOPDpatientsweredividedintomoderateorsevere
according to FEV1 ≥ or <50% predicted, respectively [15].
The diagnosis of bronchiectasis was conﬁrmed in all patients
by chest high-resolution computed tomography (HR-CT);
bronchiectasis was primary or idiopathic in 13 patients,
secondary in 6 patients [17]. All patients with IPF except
6 were on low-dose oral corticosteroids associated with
azathioprine (in 9 patients) and/or N-acetyl-cysteine (in 23
patients). Clinical data of patients and healthy subjects are
reported in Table 1.
Pulmonary function tests and other measurements used
to assess diagnosis and level of severity of the diﬀerent
diseases were performed according to standard methods.
In particular, pulmonary function tests were performed
by means of a computerized spirometer (Medgraphics,
Cardiorespiratory Diagnostics, St. Paul, Minn, USA) and the
results were expressed as percentage of CECA (European
Community for Steel and Coal) predicted values [18].
All patients were examined in a stable phase of the
disease, with no acute exacerbation in the previous month.
Informedconsentforparticipationtothestudywasobtained
from all patients.
2.2. Exhaled Breath Condensate (EBC) Collection. EBC was
collected cooling exhaled air with a speciﬁcally designed
condenser (Ecoscreen, Jaeger, Wurzburg, Germany). Sub-
jects breathed tidally for 15min through a two-way non-
rebreathing valve in order to prevent inspiratory and
respiratory air mixing and trap saliva [5]. EBC samples
were immediately stored at −80◦C until analysis, which
was performed within 6 months from the collection, as
recommended by previous studies [9, 11].
2.3. Malondialdehyde Analysis in EBC. Malondialdehyde
(MDA) concentrations were measured in EBC samples
according to the method described by L¨ arstad et al. [19].
Samples were derivatized with thiobarbituric acid (25mM in
H2PO4 0.3M,pH3.5)inawaterbathat95◦Cfor60minutes,
cooled in ice for 5 minutes, and then allowed to recover at
room temperature for 40 minutes before analysis.
Analyses were performed using a high-performance
liquid cromatography (HPLC) connected to a ﬂuorescence
detector (Binary HPLC pump 1525 and 2475 multi λ
ﬂuorescence detector, Waters, Milan, Italy), equipped with
a Polaris C18 column, 150 × 4.6mm ID, particle size
5μm (Varian, USA). Excitation and emission wavelengths
were of 532 and 553nm, respectively. The mobile phase
was composed by acetonitrile: 20mM potassium phosphate
buﬀerpH6.8(25:75,v/v),theﬂowratewas1.3mL/min.The
method had a limit of detection of 4.1nM and a recovery
of 96%. Intra- and interassay reproducibility were 1.9 and
8.7%. Figure 1 shows the Bland-Altman scattergram of two
repeatedmeasurementsof150samples:intraclasscorrelation
coeﬃcient (Ri) was 0.854.
2.4. Sputum Induction and Analysis. Sputum was performed
in 108 subjects with asthma (N = 52), COPD (N =
41) and bronchiectasis (N = 15). Sputum induction and
analysis were carried out as previously described [20, 21].
After inhaled salbutamol pretreatment, hypertonic saline
solution (HS: NaCl 4.5%w/v) was delivered by means of an
ultrasonicnebulizer(2.8mL/minoutput;DeVilbissUltraneb
2000, Somerset, Pa, USA) to induce sputum production. In
subjects with FEV1 lower than 35%, isotonic saline (IS: NaCl
0.9%w/v) was used as recommended in [20]. Nebulization
was stopped after 15min or earlier if FEV1 fell by 20% or
more from baseline values. Before and every 5min after
the start of nebulization, FEV1 was measured, and patients
were then asked to rinse their mouth and throat carefully to
discard saliva and to try to cough sputum into a container.
Sputum samples were processed within two hours from
collection; more viscid and dense sputum portions were
selected and processed as follows. Brieﬂy, samples were
homogenated by adding 0.1% (DTT) in a shaking bath at
37◦C for 15min, then centrifuged to separate cells from
supernatant. The cell pellet was resuspended in PBS for via-
bility and total cell count, and aliquots were used to prepare
slides for diﬀerential cell counts. At least 300 inﬂammatoryMediators of Inﬂammation 3
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Figure 1: Plot of diﬀerence against mean of malondialdehyde
(MDA)valuesobtainedfromtwosubsequentanalyses.Ri:intraclass
correlation coeﬃcient.
cells were counted. Macrophage, lymphocyte, neutrophil,
and eosinophil values were expressed as percent of total
inﬂammatory cells. Slides with cell viability <50% and an
amount of squamous cells such that 300 inﬂammatory
cells could not be counted were considered inadequate and
discarded.
2.5. Statistical Analysis. Functional data were expressed
as mean and standard deviation and biological data as
median and range. Diﬀerences between two groups were
tested using unpaired t-test and Mann-Whitney test for
normally and nonnormally distributed variables, respec-
tively. Diﬀerences among three or more groups were tested
using ANOVA and Kruskal-Wallis test for normally and
nonnormally distributed variables, respectively. Correlations
between functional and biological indices were evaluated
using Spearman’s rank correlation test. A P value lower
than .05 was considered as signiﬁcant.
Intraclass correlation coeﬃcient was calculated to assess
MDA interassay reproducibility (Ri values over 0.70 are
usually interpreted as satisfactory) and the Bland-Altman
plot was used to graphically represent the variability between
the two measurements [22]. The limits of agreement were
expressed as ±2 standard deviations (SDs) of the mean of
diﬀerences between the two measurements within which
95% of the repeated measures are expected to lie.
3. Results
The distribution of all measurements of MDA in EBC in
normal subjects and in patients with diﬀerent diseases is
reported in Figure 2. Healthy subjects and patients with
IPF were distributed in the lower range of MDA, while
COPD patients were mainly represented in the categories
with higher MDA concentrations.
Except for IPF patients, who showed MDA levels similar
to those of healthy controls (15.2 (4–79) versus 15.6 (4–
25)nM, resp.), all the disease groups showed higher levels of
MDA than healthy controls (Figure 3). Among asthmatics,
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Figure 2: Distribution of Malondialdehyde (MDA) in the diﬀerent
categories of subjects. COPD: chronic obstructive pulmonary
disease; IPF: Idiopathic pulmonary ﬁbrosis.
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Figure 3: Median values (interquartile range) of malondialdehyde
(MDA) in EBC in the diﬀerent categories of patients with dif-
ferent pulmonary diseases and healthy subjects; IPF: Idiopathic
pulmonary ﬁbrosis; ICS: inhaled corticosteroids; COPD: chronic
obstructive pulmonary disease.
no diﬀerence in MDA was observed between diﬃcult-to-
control and mild/moderate asthma (26.0 (14–72) versus
26.1 (6–91)nM). Comparing asthmatic patients according
to treatment, we found that ICS-treated subjects had lower
levels of MDA than untreated subjects (21.5 (6–72) versus
32.0(8–91)nM, P<. 05). COPD patients had signiﬁcantly
higher levels of MDA than asthmatic and BE subjects (37.0
(8–126) versus 26.3 (6–91)nM, P<. 05, and 19.2 (6–54)nM,
P<. 05, resp.). Within the COPD group, subjects with
severe COPD showed higher levels of MDA than patients4 Mediators of Inﬂammation
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Figure 4: Correlation between FEV1, % predicted, and malondi-
aldehyde (MDA) concentrations in COPD subjects (Spearman rank
correlation test).
with moderate COPD (39.0 (8–126) versus 29.1 (9–81)nM,
resp., P<. 05).
An inverse correlation between MDA concentrations
and FEV1 was observed both in the whole group of patients
(P<. 001, rho: −0.25) and in the COPD subgroup (P<. 05;
rho: −0.24) (Figure 4). No diﬀerence in MDA was found
dividing the whole group of patients according to their
smoking status (P = .52). Considering each disease group
separately, we found that among COPD patients, MDA
levels in current smokers were not diﬀerent from ex- and
nonsmokers (P = .11), whereas among asthmatics, current
smokers had higher MDA levels than ex- and nonsmokers
(38.5 (19–91) versus 25.5 (6–72)nM, P<. 05).
In the subgroup of 108 patients who underwent induced
sputumanalysis,norelationshipbetweenEBClevelsofMDA
and sputum inﬂammatory cell counts was found. However,
patients with high (>64% [23]) sputum neutrophils showed
signiﬁcantly higher MDA levels (P<. 05) than patients
with low sputum neutrophils, even when COPD patients
only were considered (Figure 5(a)). No diﬀerence for MDA
values was found between subjects with high (>2% [23])
or low sputum eosinophils in the whole group of patients,
but COPD subjects with high sputum eosinophils had lower
MDA levels (Figure 5(b)).
4. Discussion
We found that subjects with chronic airway disorders have
increased levels of MDA in EBC, thus conﬁrming that
oxidative stress plays a role in the pathophysiology of lung
diseases. We also found that MDA concentrations in EBC are
related to FEV1 and neutrophilic inﬂammation, particularly
in COPD patients.
MDAisamarkerofoxidativestressthatcanbemeasured,
usingdiﬀerentandsometimescomplexanalyticalprocedures
[10, 11], in blood, sputum, bronchoalveolar lavage ﬂuid,
and EBC. Lipid mediators, in fact, at body temperature
gain some volatility, thus becoming detectable also in EBC.
Some authors have shown a relationship between MDA
and other markers of severity of airway diseases [24, 25]
as well as its sensitivity to the eﬀect of treatment [26, 27],
but these data have not been conﬁrmed by others [11]. This
discrepancy may be ascribed to the diﬀerent populations
studied (considering also the heterogeneity of asthma and
COPD) and to the diﬀerent methods of measurements used.
Inourexperience,MDAmeasurementinEBCwasrepro-
ducible and accurate: interassay reproducibility was good
and not diﬀerent from what reported by other authors using
diﬀerent, more complex methods [11]. We checked storage
stability of EBC samples, just in few samples showing a
goodrepeatability;however,weanalyzedallsampleswithin6
monthsfromthecollection,assuggestedbytheinternational
recommendations and previous papers [5, 9, 11].
Our method diﬀerentiates normal subjects from patients
with diﬀerent airway diseases despite some overlapping of
single measurements. Furthermore, MDA was sensitive to
changes induced by therapeutic intervention, as shown by
the lower levels of MDA in asthmatics treated with ICS
in comparison with untreated asthmatics. This issue is
controversial in literature: while some studies reported a
reduction in MDA levels after corticosteroid treatment [24],
other studies found no diﬀerence between ICS-treated and
untreated subjects [11]. Antioxidant treatment has been
generally reported to be ineﬀective in modifying markers of
oxidative stress [28, 29]. In a preliminary study, we observed
a mild, signiﬁcant attenuation in ozone-induced EBC-MDA
increase after 4-week treatment with oral N-acetyl-cysteine
in asthmatic patients [30].
COPD subjects showed the highest values of MDA
in EBC. This observation was expected, considering that
oxidativestressplaysarelevantroleinsmoke-inducedairway
damage and chronic inﬂammation. This was conﬁrmed by
the higher levels of MDA in patients with higher percentage
of sputum neutrophils, and by the inverse correlation
betweenEBC-MDAandFEV1.Theseresultsareinagreement
with other reports [11], suggesting that MDA may be a
good marker of the severity of the disease. Similar results
were obtained in COPD when other markers of oxidative
stress were considered (such as 8-isoprostane, hydrogen
peroxide, LTB4, or other COPD-related cytokines) [31–33].
No diﬀerence was observed between current smoker and ex-
or nonsmoker COPD patients, and this might be due both
to the small number of current smokers and to the similar
patternanddegreeofairwayinﬂammationinCOPDpatients
regardless of their smoking habit [34].
In asthmatic patients, EBC-MDA levels were lower than
those observed in COPD patients, but higher than normal
subjects. There was no diﬀerence according to asthma
severity, but ICS treatment was associated with lower values
of MDA. While some authors demonstrated a signiﬁcant
decrease in blood MDA during the recovery from asthma
exacerbation treated with oral corticosteroids [24], other
authors did not ﬁnd any diﬀerence between ICS-treated
and untreated asthmatic patients [11]. In our asthmatics,
current smokers showed higher levels of EBC-MDA than
nonsmokers; this observation is in agreement with the
prominent neutrophilic airway inﬂammation in smoking
asthmatics [35].Mediators of Inﬂammation 5
COPD only
n = 41
N > 64%
n :3 0
N < 64%
n :1 1
All subjects
n = 108
N > 64%
n :6 4
N < 64%
n :4 4
P = .025
P = .028
0
20
40
60
80
100
120
140
M
D
A
(
n
M
)
(a)
COPD only
n = 41
E > 2%
n :2 5
E < 2%
n :1 6
All subjects
n = 108
E > 2%
n :6 0
E < 2%
n :4 8
P = .026
0
20
40
60
80
100
120
140
M
D
A
(
n
M
)
(b)
Figure 5: Median values (interquartile range) of malondialdehyde (MDA) in EBC according to induced sputum percentage of neutrophils
(N%) (a) and eosinophils (E%) (b) in all patients and in COPD patients only. COPD: chronic obstructive pulmonary disease.
In bronchiectasis, we found EBC-MDA levels slightly
higher than normal subjects, but lower than COPD patients.
Thisresultmaybeunexpected,consideringthatsputumneu-
trophilia is a prominent feature of this kind of patients. We
found no papers evaluating EBC-MDA levels in bronchiec-
tasis, and only one paper reports increased blood MDA
levels in children with bronchiectasis [13]. Increased levels of
other markers of oxidative stress (such as hydrogen peroxide
or pH) in EBC have been reported for bronchiectasis
[36, 37].
In IPF, no diﬀerence in EBC-MDA levels was observed in
comparison with healthy subjects. In the literature, few data
are reported showing EBC increase of hydrogen peroxide, 8-
isoprostane and nitrates in comparison with healthy subjects
[38, 39]. The low levels of EBC-MDA observed in our study
may be explained by the fact that most IPF patients were on
oral corticosteroid and/or N-acetyl-cysteine treatment.
5. Conclusions
Inconclusion,wedemonstratedthatMDAmaybeaccurately
measured in EBC of most patients with chronic pulmonary
diseases and that it is partially related to the severity of
airway obstruction and neutrophilic inﬂammation. This
was particularly evident in COPD patients, where oxidative
stress seems to play a major role in the pathophysiology
of the disease. Thus, MDA may be a promising marker
of oxidative stress in asthma and COPD. Its usefulness in
the management of these diseases, as well as for other
inﬂammatory markers, needs to be explored with well-
designed, speciﬁc studies.
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